Galacto‐conjugation of Navitoclax as an efficient strategy to increase senolytic specificity and reduce platelet toxicity

Increasing cell permeability of N-acetylglucosamine via 6-acetylation enhances capacity to suppress T-helper 1 (TH1)/TH17 responses and autoimmunity

(2019) Sung-Uk Lee et al.   PLoS One

The chemistry of senescence

(2019) Beatriz Lozano-Torres et al.   Nature Reviews Chemistry

Cellular Senescence: Defining a Path Forward

(2019) Vassilis Gorgoulis et al.   CELL

Targeting senescent cells in translational medicine

(2019) Marta Paez‐Ribes et al.   EMBO Molecular Medicine

Identification and characterization of Cardiac Glycosides as senolytic compounds

(2019) Francisco Triana-Martínez et al.   Nature Communications

A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity

(2019) Sajid Khan et al.   NATURE MEDICINE

Design, synthesis and pharmacological evaluation of new acyl sulfonamides as potent and selective Bcl-2 inhibitors

(2018) Xiaohua Liu et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Paracrine roles of cellular senescence in promoting tumourigenesis

(2018) Jose Mario Gonzalez-Meljem et al.   BRITISH JOURNAL OF CANCER

A versatile drug delivery system targeting senescent cells

(2018) Daniel Muñoz‐Espín et al.   EMBO Molecular Medicine

Hallmarks of Cellular Senescence

(2018) Alejandra Hernandez-Segura et al.   TRENDS IN CELL BIOLOGY

Fisetin is a senotherapeutic that extends health and lifespan

(2018) Matthew J. Yousefzadeh et al.   EBioMedicine

The dynamic nature of senescence in cancer

(2018) Soyoung Lee et al.   NATURE CELL BIOLOGY

Lung tumors with distinct p53 mutations respond similarly to p53 targeted therapy but exhibit genotype-specific statin sensitivity

(2017) Frances K. Turrell et al.   GENES & DEVELOPMENT

Senescence and aging: Causes, consequences, and therapeutic avenues

(2017) Domhnall McHugh et al.   JOURNAL OF CELL BIOLOGY

An OFF–ON Two-Photon Fluorescent Probe for Tracking Cell Senescence in Vivo

(2017) Beatriz Lozano-Torres et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Senescent cells: an emerging target for diseases of ageing

(2017) Bennett G. Childs et al.   NATURE REVIEWS DRUG DISCOVERY

Identification of HSP90 inhibitors as a novel class of senolytics

(2017) Heike Fuhrmann-Stroissnigg et al.   Nature Communications

Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors

(2016) Yi Zhu et al.   AGING CELL

Discovery of piperlongumine as a potential novel lead for the development of senolytic agents

(2016) Yingying Wang et al.   Aging-US

Naturally occurring p16Ink4a-positive cells shorten healthy lifespan

(2016) Darren J. Baker et al.   NATURE

Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis

(2016) Megan K. Ruhland et al.   Nature Communications

Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL

(2016) Reut Yosef et al.   Nature Communications

Cellular Senescence Promotes Adverse Effects of Chemotherapy and Cancer Relapse

(2016) Marco Demaria et al.   Cancer Discovery

Stromal-Initiated Changes in the Bone Promote Metastatic Niche Development

(2016) Xianmin Luo et al.   Cell Reports

The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs

(2015) Yi Zhu et al.   AGING CELL

ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development

(2015) Shundong Cang et al.   Journal of Hematology & Oncology

Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice

(2015) Jianhui Chang et al.   NATURE MEDICINE

Cellular senescence: from physiology to pathology

(2014) Daniel Muñoz-Espín et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Targeted Cargo Delivery in Senescent Cells Using Capped Mesoporous Silica Nanoparticles

(2012) Alessandro Agostini et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

BCL2/BCL-XL inhibition induces apoptosis, disrupts cellular calcium homeostasis, and prevents platelet activation

(2011) M. Vogler et al.   BLOOD

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

(2010) Wyndham H Wilson et al.   LANCET ONCOLOGY

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

(2008) C. Tse et al.   CANCER RESEARCH